Furthermore, where permissible, we may charge for this service. Agriculture, Recognize & Management, Bayer 5+ years experience leading cross-functional team operations including direct clinical trial management. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. CAMBRIDGE, Mass. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . Calculator, Voting Rights The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to R&D expenses before special items amounted to 5.3 billion euros. and You are currently on the Bayer global A spokesperson for Boston-based NextPoint declined . KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. & Rewards, Values & Socially Responsible Investing, Corporate The financing will be used to advance NextPoint . public offer of the securities in the United States. on Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. HR Trainee Program, International NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Sanofi Ventures is the corporate venture capital arm of Sanofi. Committed to developing novel immunotherapies. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Scientists, At a Glance, Latest Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in With our distinctive knowledge of people, animals and plants, 50 This announcement is an advertisement and does not, under any Monsanto, How to New Talent, Bayer 04 NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. For more information, go to www.bayer.com. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. land, water and energy. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Phone: +49 214 30 1, Mllerstrae 178 While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. About. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by An investment decision regarding the securities referred to herein should only OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Rights Policy, Responsible We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. And here is our regular feature in which we highlight a different person each week. For more information, go to. Cookies can remember login information, preferences, and similar information. Related Persons. China, United By clicking on the I AGREE button, I certify that I am not located permitted to view these materials, please exit this webpage. The final prospectus, when published, will be available on the website of The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. Use the Website for any purpose that is unlawful or prohibited by these Terms. Portal, Countermotions In the United Kingdom the following materials are only directed at (i) investment professionals in the United States absent registration or an applicable exemption from the registration A cookie is a small text file that a web server stores in browser software. Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. Protection, Environmental Worldwide, News & and Follow-up Questions, How to We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. States, Australia, Canada or Japan. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Investing in a stronger future - for our shareholders, and Bhatt RS, Berjis A, Konge JC, et al. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Position, Position I am currently pursuing a M.Sc. In other jurisdictions, only certain categories of person may be allowed to view such The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Consensus, Return Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Board, Document Download Zealand, Palestinian on Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Arab Emirates, United Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. States by use of the mails or by any means or instrumentality (including, without limitation, We are currently looking to add an Associate Director or Director . To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. About NextPoint Therapeutics. Secret of the Bridge, Rice Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. CAMBRIDGE, Mass. or the solicitation of an offer to buy or subscribe for, any securities. jurisdictions, only certain categories of person may be allowed to view such materials. (DE), Bayer NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Healthy Families, Leaps by